Marc C. Smaldone, MD, MSHP

Articles by Marc C. Smaldone, MD, MSHP

Economic Burden of Oral Tyrosine Kinase Inhibitors Among Privately Insured Patients Diagnosed With Metastatic Renal Cell Carcinoma

BySimon P. Kim, MD, MPH,Cary P. Gross, MD,Quoc-Dien Trinh, MD,Marc C. Smaldone, MD, MSHP,R. Houston Thompson, MD,Sarah P. Psutka, MD,Holly Van Houten, BA,Leona C. Han, BA,Robert Abouassaly, MD

February 11th 2016

Study investigate the economic burden from the total costs, private insurance reimbursement, and out-of-pocket costs for oral TKI agents among metastatic RCC patients.

Latest Updated Articles

Economic Burden of Oral Tyrosine Kinase Inhibitors Among Privately Insured Patients Diagnosed With Metastatic Renal Cell Carcinoma
February 11th 2016

Marc C. Smaldone, MD, MSHP

Articles by Marc C. Smaldone, MD, MSHP

Economic Burden of Oral Tyrosine Kinase Inhibitors Among Privately Insured Patients Diagnosed With Metastatic Renal Cell Carcinoma

Latest Updated Articles

Trending on Pharmacy Times

Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice

Updated 2025-2026 COVID-19 Vaccine Nearly Halved ED Visits, Hospitalizations in CDC-Funded Study

Olezarsen Receives FDA Approval to Reduce Triglycerides, Risk of Acute Pancreatitis in Severe Hypertriglyceridemia

The Biosimilar Conversation Nobody Is Having at the Pharmacy Counter: Why Adoption Is Still Struggling and What We Can Do About It

FDA Accepts NDA for Giredestrant in Early-Stage ER-Positive Breast Cancer Under Priority Review